Project Grant R01AI188897
Award Date
7/25/25
Completion Date
6/30/29
Dollars Obligated
$3.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $166,162 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, Davis (UC Davis). The grant, awarded on September 15, 2024, will support research to characterize the ecological drivers and longitudinal dynamics of coronavirus cross-species transmission in bat populations. The project aims to provide insights into the origins and emergence of...
The University of Colorado-Denver received a $782,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant supports research to define mechanisms by which arthritogenic alphaviruses, such as chikungunya and Ross River viruses, evade CD8+ T cell-mediated clearance. The research aims to investigate how type I interferon signaling restricts myeloid cell infection...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $254,250 to New York University (NYU) from July 1, 2025 to June 30, 2027. The funding supports research to understand how pathogenic alphaviruses, such as chikungunya virus, infect and spread through human microvascular endothelial cells. The research aims to identify viral and host factors that restrict alphavirus...
The University of California, Davis received a $225,839 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, titled "Vaccine Induction of Salmonella-Specific Th1 Memory Cells," aims to investigate the role of tissue-resident memory CD4 T cells in providing protection against systemic Salmonella infections, and to evaluate the use of an mRNA nanoparticle vaccine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of California, Davis. The grant, titled "OPTIMAL T-CELL SUPPORT FOR HIV NEUTRALIZING ANTIBODY INDUCTION TO FUSION PEPTIDE-INCLUSIVE REGIMENS (OPTI-FLIP)", will fund the development of an HIV vaccine regimen that elicits cooperative interactions between fusion peptide-directed...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The goal of this 2-year award, with a period of performance from November 2024 to October 2026, is to develop a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded interleukin-10 (IL-10) protein, in order to prevent primary CMV infection and reduce the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Idaho. The grant will fund research to better understand the developmental cycle of chlamydial bacteria, which cause various infectious diseases in humans. Specifically, the project aims to develop a CRISPR-based knockdown screen to assess the role of essential genes in regulating chlamydial...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $126,174 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of California, Davis (UC Davis). The grant, with a performance period from May 29, 2025 to Dec 31, 2027, will support research to investigate the local immune response in bacterial skin infections using a novel skin-on-a-chip model. Specifically, the project aims to demonstrate the role of...